Varoglutamstat

CAS No.	1276021-65-8
MDL No.	N/A
MF	C₁₉H₂₀N₄O₂
MW	336.40
InChI Key	XHIKZWOEFZENIX-GOSISDBHSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1276021-65-8
Product Name	Varoglutamstat

Associated Conditions

Alzheimer disease

* The information provided here is compiled from public sources and is for reference only.

Varoglutamstat

CAS No.	1276021-65-8
MDL No.	N/A
MF	C₁₉H₂₀N₄O₂
MW	336.40
InChI Key	XHIKZWOEFZENIX-GOSISDBHSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	1276021-65-8
Product Name	Varoglutamstat

Associated Conditions

Alzheimer disease

* The information provided here is compiled from public sources and is for reference only.

Varoglutamstat

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Associated Conditions

Varoglutamstat

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Associated Conditions

Documentation

Varoglutamstat

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Associated Conditions

Related Articles

Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy.

Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease.

Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases.

Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy.

Varoglutamstat

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Associated Conditions

Related Articles

Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy.

Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease.

Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases.

Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy.

Documentation